Company Attovia Therapeutics, Inc.

Stocks

ATTO

US04987L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-27 EDT			5-day change	1st Jan Change
21.46 ^USD	+9.77%		+6.19%	-

08-14	Attovia Therapeutics Insider Bought Shares Worth $10,285,000, According to a Recent SEC Filing	MT
08-05	Attovia Therapeutics, Inc.(NasdaqGM:ATTO) added to NASDAQ Composite Index	CI

Business description: Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.

Number of employees: 44

Sales by Activity: Attovia Therapeutics, Inc.

Fiscal Period: December	2024 (USD)	2025 (USD)
Development of Therapeutic Products in The Fields of Immune-Mediated Diseases	-	1.35M

See all business segments

Geographical breakdown of sales: Attovia Therapeutics, Inc.

Fiscal Period: December	2024 (USD)	2025 (USD)
United States of America	-	1.35M

See all geographic segments

Executive Committee: Attovia Therapeutics, Inc.

Manager	Title	Age	Since
Hangjun Zhan CTO	Chief Tech/Sci/R&D Officer	-	2022-12-15
Petter Veiby CTO	Chief Tech/Sci/R&D Officer	61	2023-05-31
Tao Fu CEO	Chief Executive Officer	54	2023-03-31
Zaneta Odrowaz SEC	Corporate Secretary	42	2023-03-31
Steven Chan DFI	Director of Finance/CFO	54	2024-09-30

See ATTOVIA THERAPEUTICS, INC. governance

Composition of the Board of Directors: Attovia Therapeutics, Inc.

Director	Title	Age	Since
Aaron Royston BRD	Director/Board Member	42	2023-05-31
Tao Fu BRD	Director/Board Member	54	2023-03-31
James Topper CHM	Chairman	64	2023-05-31
Angie You BRD	Director/Board Member	53	2024-06-30
Mitchell Gold BRD	Director/Board Member	59	2024-06-30
John Smither BRD	Director/Board Member	73	2026-06-30
Colin Walsh BRD	Director/Board Member	40	2024-04-30

Composition of the Board of Directors

Shareholders: Attovia Therapeutics, Inc.

Name	Stocks	%	Valuation
Frazier Life Sciences Management LP 16.2 %	6,968,703	16.2 %	70 $
venBio Partners LLC 9.718 %	4,181,367	9.718 %	42 $
Alamar Holdco LLC 7.505 %	3,229,279	7.505 %	32 $
Goldman Sachs & Co. LLC (Private Banking) 5.66 %	2,435,641	5.66 %	24 $
Redmile Group LLC 5.033 %	2,165,708	5.033 %	22 $

List of ATTOVIA THERAPEUTICS, INC. shareholders

Company details: Attovia Therapeutics, Inc.

Attovia Therapeutics

1091 Industrial Road

94070, San Carlos

http://www.attovia.com

address Attovia Therapeutics, Inc.(ATTO)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ATTOVIA THERAPEUTICS, INC.	+9.77%	+6.19%	-	-	923M
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	70.64B
ARGENX SE	-0.37%	+0.24%	+50.05%	+92.55%	66.11B
BIONTECH SE	-1.03%	+0.46%	+8.14%	-5.28%	27.98B
INSMED INCORPORATED	-2.41%	-2.95%	-9.77%	+455.82%	26.51B
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	-0.69%	+63.18%	+11.93%	26.44B
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	20.4B
GENMAB A/S	+0.21%	+0.98%	+34.70%	-17.41%	20.17B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-4.37%	+13.33%	+531.29%	15.99B
EXELIXIS, INC.	-1.50%	+2.92%	+43.50%	+151.30%	13.69B
Average	+0.74%	+1.51%	+59.29%	+193.80%	28.89B
Weighted average by Cap.	+0.38%	+0.67%	+56.49%	+154.50%